Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients

摘要

Magnetic resonance imaging (MRI) or ultrasonography (US) alone is limited in the ability to predict the pathologic complete response (pCR) accurately after neoadjuvant chemotherapy. We found that MRI combined with second-look US for predicting pCR was useful compared with MRI alone, especially for estrogen receptor-negative/human epidermal growth factor receptor-positive tumors. However, it was difficult to predict the residual in situ component.